Pharmalittle: We're reading about PEPFAR and a Gilead drug, the FDA's rejection letters, and much more

The Trump administration, Gilead Sciences, and The Global Fund will proceed with a program to provide a groundbreaking HIV prevention drug to up to 2 million people in low- and middle-income countries, despite prior funding uncertainties stemming from potential foreign aid cuts to key initiatives like PEPFAR. Concurrently, the U.S. Food and Drug Administration (FDA) is enhancing transparency in drug review by committing to release complete response letters (CRLs) for rejected drug applications soon after they are issued, having already disclosed 89 previously hidden CRLs from 2024-2025. This increased regulatory disclosure provides crucial insight into development hurdles for pharmaceutical and biotech investors.

Analysis

Two significant developments are impacting the pharmaceutical and biotech sectors. Firstly, Gilead Sciences (GILD) has gained clarity on a major global health initiative, as the Trump administration confirmed its collaboration with the company and The Global Fund to supply an HIV prevention drug to 2 million people in low- and middle-income countries. This proceeds despite earlier doubts stemming from potential cuts to foreign aid and the fact that only half of the $6 billion budget for the President’s Emergency Plan for AIDS Relief (PEPFAR), a key funding partner, has been appropriated. While Gilead will provide the drug at cost, resolving this uncertainty is a positive reputational development. Secondly, the U.S. Food and Drug Administration (FDA) has materially increased regulatory transparency by committing to release complete response letters (CRLs) for rejected drug applications. The agency has already made public 89 previously undisclosed CRLs from 2024-2025, directly impacting companies such as Replimune (REPL), Capricor Therapeutics (CAPR), and Ultragenyx (RARE) by revealing past regulatory rejections. This policy shift removes the information advantage previously held by drugmakers regarding clinical setbacks and provides investors with more direct, timely insight into development hurdles.

Key Decisions for Investors

• For Gilead Sciences (GILD), the confirmation of the HIV drug program is a de-risking event that bolsters its ESG profile and removes a near-term overhang, supporting a stable outlook despite the 'at-cost' nature of the supply agreement.
• Investors in Replimune (REPL), Capricor (CAPR), and Ultragenyx (RARE) should re-evaluate their positions, as the public disclosure of historical complete response letters introduces new, negative data points that may impact perceived drug development timelines and regulatory risk.
• Across the broader biotech sector, the FDA's new policy on CRLs increases event-driven volatility risk; it is now prudent to incorporate the likelihood of faster, more direct public disclosure of regulatory rejections into investment theses and valuation models for clinical-stage companies.